Desloratadine
 | |
 | |
| Clinical data | |
|---|---|
| License data |
|
| Pregnancy category |
|
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Rapidly absorbed |
| Protein binding | 85% |
| Metabolism | Liver |
| Elimination half-life | 27 hours |
| Excretion | 40% as conjugated metabolites into urine Similar amount into the feces |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.166.554 |
| Chemical and physical data | |
| Formula | C19H19ClN2 |
| Molar mass | 310.82 g·mol−1 |
Desloratadine is a drug used to treat allergies. It is marketed under several trade names such as NeoClarityn, Claramax, Clarinex and Aerius. It is an active metabolite of loratadine, which is also on the market.
Available forms
Desloratadine is available as tablets, solution and oral suspension.
Mechanism of action
Desloratadine is a tricyclic antihistamine, which has a selective and peripheral H1-antagonist action. It has a long-lasting effect and does not cause drowsiness because it does not readily enter the central nervous system.[1]
Side effects
Most common side-effects are fatigue, drowsiness, dry mouth, headache, and gastrointestinal disturbances.
Desloratadine vs. loratadine
Desloratidine is the major metabolite of loratadine. There are no head to head randomised controlled trials of the two drugs. A survey of patients dissatisfied with loratadine published in August 2003 reported equal or better satisfaction with desloratadine[2], concluding:
- "When severity of disease was controlled for in the analysis, a pattern emerged suggesting greater levels of satisfaction amongst loratadine dissatisfied patients who converted to desloratadine. Point estimates suggest a consistent pattern favoring desloratadine patient satisfaction, with statistically significant results reported for sum of adverse effects, nighttime awakening due to symptoms, symptom severity just prior to the next dose, and overall satisfaction (p < 0.05)."
A November 2003 article published in the journal American Family Physician about the safety, tolerability, effectiveness, price, and simplicity of desloratadine concluded the following:[3]
- "Desloratadine is similar in effectiveness to fexofenadine and would be expected to produce results similar to loratadine and other nonsedating antihistamines. There is no clinical advantage to switching a patient from loratadine to desloratadine. However, it may be an option for patients whose medical insurance no longer covers loratadine if the co-pay is less than the cost of the over-the-counter product."
References
- ^ Mann R, Pearce G, Dunn N, Shakir S (2000). "Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice". BMJ. 320 (7243): 1184–6. PMID 10784544.
{{cite journal}}: CS1 maint: multiple names: authors list (link) - ^ Glass D, Harper A (Aug 13, 2003). "Assessing satisfaction with desloratadine and fexofenadine in allergy patients who report dissatisfaction with loratadine". BMC Fam Pract. 4: 10. PMID 12917016.
- ^ See S (2003). "Desloratadine for allergic rhinitis". Am Fam Physician. 68 (10): 2015–6. PMID 14655812.